Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Open accessThe DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Abstract
Inactivation of the von Hippel-Lindau tumor suppressor gene is linked to the development of hereditary (VHL Disease-associated) and sporadic clear cell carcinoma of the kidney. The VHL gene product, pVHL, targets the heterodimeric transcription factor HIF for polyubiquitination, and restoration of pVHL function in VHL(-/-) renal carcinoma cells suppresses their ability to form tumors in nude mice. Here we show that tumor suppression by pVHL can be overridden by a HIF variant that escapes pVHL control. These studies prove that HIF is a critical downstream target of pVHL and establish that activation of HIF target genes can promote tumorigenesis in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, these studies were performed using 786–0 cells, which are pVHL deficient RCC cells that intrinsically lack HIF-1α expression, and may have thus adapted to selectively depend on HIF-2α [26–28].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [26]
In the citing paper
“Specifically, the pro-tumorigenic role of HIF-2α was initially proposed based on studies showing that overexpression of HIF-2α, but not HIF-1α, abrogated the ability of pVHL re-expression to inhibit xenograft formation, and the converse that HIF-2α shRNA prevented tumor xenograft formation [26–28].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [26]
Citations
Cites
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535 · cited 2×
“The VHL gene resides on chromosome 3p25, and individuals with VHL disease are is governed by oxygen-dependent hydroxylation of conserved proline residues in HIF by members of the Egl9 family (Bruick germline VHL / heterozygotes. Tumors develop in this setting when the remaining wild-type VHL allele is mutated or lost.…”
BackgroundThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 3×
“The VHL gene resides on chromosome 3p25, and individuals with VHL disease are is governed by oxygen-dependent hydroxylation of conserved proline residues in HIF by members of the Egl9 family (Bruick germline VHL / heterozygotes. Tumors develop in this setting when the remaining wild-type VHL allele is mutated or lost.…”
BackgroundSelf-citationEpstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
(2011) · SpringerReference · doi:10.1007/springerreference_33432 · Cited by 2,510
(1999) · PubMed · Cited by 2,204
Regulation of Mammalian O 2 Homeostasis by Hypoxia-Inducible Factor 1
Semenza, G. L. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.551 · Cited by 1,914 · cited 1×
“…HIF has been suggested to mutants may be defective for recognizing one or more proteins underlie the characteristic changes in tumor cell metabolism that play important roles in regulating the growth and behavior referred to as the Warburg Effect (Dang and Semenza, 1999; of adrenal medullary cells.”
BackgroundMutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730
Research works printed but not linked: 2
- Atlas, 1992, Growth regulation of human renal carcinoma cells, Cancer Res., 52, 3335
- de Paulsen, 2001, Role of transforming growth factor-α in VHL−/− clear cell renal carcinoma cell proliferation, Proc. Natl. Acad. Sci. USA, 13, 1387
Cited by
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Regulation of angiogenesis by hypoxia: role of the HIF system
Pugh, C. W., & Ratcliffe, P. J. (2003) · Nature Medicine · doi:10.1038/nm0603-677 · Cited by 2,520
Hypoxia, HIF1 and glucose metabolism in the solid tumour
Denko, N. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2468 · Cited by 1,707
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Metadata
- Authors
- Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Kaelin, William G
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2002-04
- Volume
- 1
- Issue
- 3
- Pages
- 237-246
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2081460564
- Cited by
- 761
- References
- 83
- Citations by year
- 2026: 9 · 2025: 19 · 2024: 12 · 2023: 25 · 2022: 28 · 2021: 22 · 2020: 29 · 2019: 27 · 2018: 26 · 2017: 23 · 2016: 29 · 2015: 26 · 2014: 35 · 2013: 32 · 2012: 38
- FWCI
- 16.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4125 d)
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- McKnight Foundation
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Keywords
- von Hippel-Lindau protein, hypoxia-inducible factor, tumor suppression, clear cell renal cell carcinoma, von Hippel-Lindau disease, polyubiquitination, HIF target genes, carcinogenesis, transcription factor regulation
- MeSH terms
- Animals, Carcinoma, Renal Cell, Cycloheximide, Humans, Immunoenzyme Techniques, Kidney Neoplasms, Ligases, Mice, Nude, Monosaccharide Transport Proteins, Mutation, Plasmids, Protein Synthesis Inhibitors, Retroviridae, Transcription Factors, Transfection, Tumor Cells, Cultured, Blotting, Western, Down-Regulation, Genes, Tumor Suppressor, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Glucose Transporter Type 1, Mice, Von Hippel-Lindau Tumor Suppressor Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. https://app.cochat.ai/papers/10.1016/s1535-6108(02)00043-0
- The paper
- Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002). Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. https://doi.org/10.1016/s1535-6108(02)00043-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.